Urovant Sciences Ltd. (UROV) financial statements (2020 and earlier)

Company profile

Business Address 5281 CALIFORNIA AVENUE
IRVINE, CA 92617
State of Incorp.
Fiscal Year End March 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
TTM
3/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments13285
Cash and cash equivalents13285
Restricted cash and investments00
Receivables0 
Other undisclosed current assets1013
Total current assets:14299
Noncurrent Assets
Operating lease, right-of-use asset3
Property, plant and equipment11
Restricted cash and investments11
Other undisclosed noncurrent assets00
Total noncurrent assets:52
TOTAL ASSETS:148100
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1712
Accounts payable22
Accrued liabilities1510
Interest and dividends payable0 
Debt44 
Due to related parties00
Total current liabilities:6212
Noncurrent Liabilities
Long-term debt and lease obligation9014
Long-term debt, excluding current maturities8714
Operating lease, liability3
Total noncurrent liabilities:9014
Total liabilities:15225
Stockholders' equity
Stockholders' equity attributable to parent(4)75
Common stock00
Common stock, share subscribed but unissued, subscriptions receivable(0)(0)
Additional paid in capital266250
Accumulated other comprehensive income00
Accumulated deficit(271)(176)
Total stockholders' equity:(4)75
TOTAL LIABILITIES AND EQUITY:148100

Income statement (P&L) ($ in millions)

12/31/2019
TTM
3/31/2019
Operating expenses(121)(111)
Operating loss:(121)(111)
Nonoperating expense
(Other Nonoperating expense)
(0)(0)
Loss from continuing operations before equity method investments, income taxes:(121)(111)
Other undisclosed loss from continuing operations before income taxes(3)(0)
Loss from continuing operations before income taxes:(124)(111)
Income tax expense(0)(0)
Net loss available to common stockholders, diluted:(124)(111)

Comprehensive Income ($ in millions)

12/31/2019
TTM
3/31/2019
Net loss:(124)(111)
Comprehensive loss:(124)(111)
Other undisclosed comprehensive income, net of tax, attributable to parent00
Comprehensive loss, net of tax, attributable to parent:(124)(111)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: